(Total Views: 960)
Posted On: 06/28/2020 1:43:32 PM
Post# of 153940
I believe that the existing CCR5 mAbs are allosteric modulators (completely block and disable normal GCPR functioning.
Leronlimab blocks CCL5 / RANTES binding, but does not disable the functioning of CCR5. There literally dozens of functions for each of these GCPRs, so completely disabling their functioning is not an ideal approach.
The analogy I used to explain this to my brother is putting an enormous bouncer in front of the door to choose whom you let in vs. nailing the door shut.
Leronlimab blocks CCL5 / RANTES binding, but does not disable the functioning of CCR5. There literally dozens of functions for each of these GCPRs, so completely disabling their functioning is not an ideal approach.
The analogy I used to explain this to my brother is putting an enormous bouncer in front of the door to choose whom you let in vs. nailing the door shut.
(4)
(0)
